KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) Non Operating Income (2017 - 2026)

Neogenomics filings provide 15 years of Non Operating Income readings, the most recent being -$12000.0 for Q1 2026.

  • On a quarterly basis, Non Operating Income fell 118.46% to -$12000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $219000.0, a 529.41% increase, with the full-year FY2025 number at $296000.0, up 178.1% from a year prior.
  • Non Operating Income hit -$12000.0 in Q1 2026 for Neogenomics, down from $84000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $730000.0 in Q2 2023 to a low of -$431000.0 in Q4 2024.
  • Median Non Operating Income over the past 5 years was -$1000.0 (2022), compared with a mean of $19764.7.
  • Biggest five-year swings in Non Operating Income: tumbled 484.0% in 2023 and later surged 24200.0% in 2025.
  • Neogenomics' Non Operating Income stood at -$1000.0 in 2022, then surged by 12500.0% to $124000.0 in 2023, then tumbled by 447.58% to -$431000.0 in 2024, then skyrocketed by 119.49% to $84000.0 in 2025, then plummeted by 114.29% to -$12000.0 in 2026.
  • The last three reported values for Non Operating Income were -$12000.0 (Q1 2026), $84000.0 (Q4 2025), and -$335000.0 (Q3 2025) per Business Quant data.